4.7 Article

MAP3K11 is a tumor suppressor targeted by the oncomiR miR-125b in early B cells

Journal

CELL DEATH AND DIFFERENTIATION
Volume 23, Issue 2, Pages 242-252

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/cdd.2015.87

Keywords

-

Funding

  1. Deutsche-Forschungsgemeinschaft [EXC294]
  2. Tiroler Zukunftsstiftung
  3. Baden-Wurttemberg foundation
  4. Medical University Innsbruck (MUI)
  5. Austrian Science Fund (FWF) [P23510-B19, SFB-021]
  6. MCBO [W1101]
  7. Austrian Science Fund (FWF) [P 23510] Funding Source: researchfish
  8. Austrian Science Fund (FWF) [P23510] Funding Source: Austrian Science Fund (FWF)

Ask authors/readers for more resources

MicroRNAs (miRNAs) are a class of small, non-coding RNAs that posttranscriptionally regulate gene expression and thereby control most, if not all, biological processes. Aberrant miRNA expression has been linked to a variety of human diseases including cancer, but the underlying molecular mechanism often remains unclear. Here we have screened a miRNA expression library in a growth factor-dependent mouse pre-B-cell system to identify miRNAs with oncogenic activity. We show that miR-125b is sufficient to render pre-B cells growth factor independent and demonstrate that continuous expression of miR-125b is necessary to keep these cells in a transformed state. Mechanistically, we find that the expression of miR-125b protects against apoptosis induced by growth factor withdrawal, and that it blocks the differentiation of pre-B to immature B cells. In consequence, miR-125b-transformed cells maintain expression of their pre-B-cell receptor that provides signals for continuous proliferation and survival even in the absence of growth factor. Employing microarray analysis, we identified numerous targets of miR-125b, but only reconstitution of MAP3K11, a critical regulator of mitogen-and stress-activated kinase signaling, interferes with the cellular fitness of the transformed cells. Together, this indicates that MAP3K11 might function as an important tumor suppressor neutralized by oncomiR-125b in B-cell leukemia.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available